8 results about "Insulin deficiency" patented technology

It is considered that diabetes-associated dementia is mainly caused by insulin resistance and relative insulin deficiency in the brain. Delivery of drugs to the brain is inhibited by the blood-brain barrier, and therefore, there has been so far no drug that provides excellent drug delivery to the brain. Therefore, there has been no wonder drug for diabetes-associated dementia. LPSs have a high molecular weight and therefore do not pass through the blood-brain barrier. It is possible to provide a composition for a drug, food, or the like that has the effect of preventing and treating impairment due to diabetes-associated dementia, by means of a lipopolysaccharide derived from a bacterium belonging to the genus Pantoea. A lipopolysaccharide derived from a bacterium belonging to the family Enterobacteriaceae is confirmed to be safe when used for oral or transdermal administration in the form of food, cosmetics, feed, or the like, and thus can be expected to provide prophylactic and therapeutic effects with a low risk of side effects.

The application relates to an induced type 2 diabetes mellitus feed and application thereof in establishing a type 2 diabetes mellitus animal model, and relates to the field of experimental animal models, and particularly relates to an induced type 2 diabetes mellitus feed and application thereof in establishing a type 2 diabetes mellitus animal model. The application aims at solving the problems of long modeling time, instability and easy change into a type 1 diabetes mellitus model of the existing type 2 diabetes mellitus animal model establishing method. The feed comprises desulfurization vibrio powder, symbiotic clostridium powder and high-fat high-sugar feed. The method comprises the following steps: drying desulfurization vibrio liquid and symbiotic clostridium liquid into powder, uniformly mixing the powder and the high-fat high-sugar feed, and extruding into a column shape by using an extrusion molding machine. The application significantly shortens the establishment time of the type 2 diabetes mellitus animal model, does not need to inject a high-dose STZ, and does not cause the type 1 diabetes mellitus model of absolute insulin deficiency of rats in the case of using a higher concentration of STZ induction. The induced type 2 diabetes mellitus feed is used for establishing the type 2 diabetes mellitus animal model.

The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.

The present disclosure provides compositions of stem cell-derived pancreatic islet cells engineered for improved engraftment and methods of use thereof for treating a subject having an insulin deficiency.

This disclosure provides cell-based compositions for the treatment of diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for the treatment of insulin deficiency-related diseases.

Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.

The application provides a hydrogel system and a preparation method and application thereof. The hydrogel system provided by the application comprises oxidized hyaluronic acid, chitosan, perfluorotributylamine and a vascular growth factor, and can provide oxygen for islet cells, promote in-situ islet vascular reconstruction, inhibit islet cell apoptosis and promote insulin secretion, thereby providing a new strategy for islet transplantation and even treatment of diseases caused by insulin deficiency or insufficiency.